Does ADHD Shorten Life Expectancy? What Studies Reveal About Early Death, Causes, and Medication

Yes. In large population studies, people with attention-deficit/hyperactivity disorder (ADHD) have higher rates of premature death than people without ADHD. But this does not mean ADHD directly causes every excess death, that everyone with ADHD will die young, or that a diagnosis determines an individual’s lifespan.

A systematic review published in JAMA Network Open on October 19, 2026 found a 71% higher hazard of death from any cause among people with ADHD. The review included 19 studies with a combined 15.9 million participants. It also found higher mortality associated with suicide, injuries, and natural causes, alongside an association between ADHD medication use and lower overall mortality.

Separately, a 2025 UK study of adults with diagnosed ADHD estimated life-expectancy gaps of 6.78 years for men and 8.64 years for women, compared with matched adults without the diagnosis. Those are population-level estimates for a particular diagnosed group, not years that every person with ADHD can expect to lose.

The critical questions are what these numbers measure, why the association exists, and which risks may be reduced through better treatment and healthcare. The evidence is substantial, but it is not a prediction of any one person’s future.

What did the 2026 ADHD mortality study actually find?

Researchers led by Lucy Corrigan at the University of Liverpool, with collaborators including University College London, reviewed published observational studies comparing mortality in people with and without ADHD. They also examined studies comparing mortality among people with ADHD who did or did not use ADHD medication.

The October 2026 JAMA Network Open meta-analysis included 19 studies covering 15,920,970 participants, but only 12 studies contributed to the pooled meta-analyses. The remaining seven were summarized separately. The 15.9 million figure is the combined review sample, not the number behind every estimate below.

Source: Corrigan et al., 2026. The medication result comes from only three studies and uses a different comparison group from the first four rows. All figures are observational associations, not demonstrated causal effects.

The findings are not all new discoveries. Earlier research had already linked ADHD to increased mortality. What the 2026 review added was an updated synthesis across causes of death and a pooled assessment of the medication association. An earlier 2022 systematic review in JAMA Pediatrics had found elevated overall and unnatural-cause mortality, but less clear evidence for natural-cause deaths. The newer review identified a statistically significant, though smaller, natural-cause association.

There is an important date detail: the 2026 paper’s literature search ended July 8, 2025. Its publication date does not mean it incorporated every study released during 2026.

Why the 71% figure needs caution

The review reported very high variation between studies for overall mortality, measured by an I² statistic of 98%. In practical terms, studies generally pointed toward higher mortality among people with ADHD, but the size of that association differed substantially by population, methods, and circumstances.

The researchers also drew from studies using different ways to identify ADHD, including clinical diagnoses, reported traits, and, in one study, genetic risk scores. They noted inconsistent adjustment for factors such as socioeconomic conditions and co-occurring illnesses. Reliable analyses of how risk differed by age or sex were not possible from the available data.

The 71% is a pooled research finding, not a risk multiplier that can responsibly be applied to every adult or child with ADHD.

Does a 71% higher mortality hazard mean a 71% chance of dying?

No. A hazard ratio compares the rate at which an outcome occurs over the period researchers observe people. A hazard ratio of 1.71 means the estimated mortality hazard in one group was 1.71 times that in the comparison group. It does not mean 71 out of 100 people with ADHD will die, that the lifetime probability of death is 71% higher, or that ADHD automatically removes a fixed number of years from life.

To understand the consequence, readers also need an absolute baseline: how many deaths occurred, in what population, and over what period?

A useful example comes from a 2015 nationwide Danish study in The Lancet. Researchers followed approximately 1.92 million people, including 32,061 with ADHD, and reported these observed rates:

A person-year is one person observed for one year. Thus, the Danish figures represent mortality rates across accumulated observation time, not the proportion of people who died over an entire lifetime.

The distinction matters. The relative disparity is substantial, but the absolute number of deaths in this comparatively young cohort was small. The researchers followed participants only to a maximum age of about 32, so these particular rates should not be treated as annual mortality estimates for middle-aged or older adults.

Nor should they be multiplied by 1.71: the Danish figures come from a different study with a different population and statistical model. They serve to illustrate why relative risk and absolute risk must be reported separately.

How many years does ADHD reduce life expectancy?

The most widely circulated answer is approximately seven years for men and nine for women, but the origin and limitations of those numbers are essential.

In a UK matched-cohort study published in The British Journal of Psychiatry in 2025, researchers compared 30,039 adults with diagnosed ADHD with 300,390 adults matched on age, sex, and primary care practice. They analyzed recorded deaths and used statistical life tables to estimate life expectancy.

These are modeled period-life-expectancy estimates based on UK primary-care data, not the average observed age at death among all participants. Differences may not apply to undiagnosed ADHD or to other countries and generations.

Why these figures are not an individual prognosis

Only about 0.32% of adults in the underlying UK records had a documented ADHD diagnosis. The authors estimated this represented roughly one in nine adults likely to have ADHD. Therefore, the diagnosed group may not have resembled the much larger population of adults with ADHD who were undiagnosed.

Adults who came to clinical attention may have had more severe symptoms, more co-occurring medical or psychiatric conditions, or greater healthcare needs. The authors explicitly warned that the results might not generalize to all adults with ADHD.

Life tables are also a projection from mortality patterns, not a clock that follows each participant from birth to death. Changes in care, smoking rates, health conditions, and social circumstances could change future outcomes. The UK study was also included in the 2026 review, so the two findings should not be treated as completely independent sets of evidence.

A life-expectancy gap describes a population-level health inequality under the study’s assumptions. It does not establish that a particular person with ADHD will die six, seven, eight, or nine years early.

Why is ADHD linked to premature death?

There is no single proven mechanism. ADHD affects attention, impulse regulation, activity levels, and executive functioning, but the conditions associated with premature death span mental health, injury risk, physical health, and access to effective care. Much of the excess mortality may involve factors that occur alongside ADHD rather than a direct biological effect of the diagnosis itself.

1. Accidental injuries and transport incidents

Attention and impulse-control difficulties may affect the handling of safety-sensitive activities. Researchers have also identified higher rates of co-occurring substance-use disorders and other conditions that can compound injury risk.

In the 2015 Danish mortality study, accidents were the most common cause of death among participants with ADHD. The 2026 pooled analysis likewise found a 55% higher hazard of death from intentional or unintentional injuries.

This does not establish that every such injury was caused by distraction or impulsivity. An injury-related death can reflect many interacting circumstances, including environmental hazards, co-occurring conditions, and access to support.

2. Suicide and co-occurring mental health conditions

The 2026 review found an 89% higher relative hazard of suicide death. That is a serious population-level signal, not an estimate of any individual’s probability of suicide.

ADHD frequently co-occurs with depression, anxiety, substance-use disorders, and other mental health conditions. A 2019 Swedish population study published in JAMA Psychiatry found that psychiatric comorbidities contributed importantly to mortality disparities, particularly among adults with ADHD.

The newer review also discusses social exclusion, disadvantage, and stigma as possible contributors. None of these factors should be reduced to the claim that ADHD itself inevitably produces suicidal thoughts or behavior.

If someone is experiencing suicidal thoughts or an immediate mental health crisis in the United States, they can call or text 988 or use the 988 Suicide & Crisis Lifeline. A statistical article cannot substitute for direct support when someone is at risk.

3. Physical health, smoking, and cardiovascular risk

The newer review found a smaller but statistically significant association with natural-cause mortality. Natural causes refer primarily to disease-related deaths, rather than injuries or suicide.

Possible contributors include smoking, obesity, metabolic conditions, cardiovascular disease, and other illnesses. These factors deserve attention because they may accumulate over many years and because medical prevention can address some of them. The review does not establish how much of the natural-cause excess is attributable to any one condition.

A 2026 study in Frontiers in Psychiatry followed a British birth cohort and examined whether smoking and midlife cardiovascular risk factors helped explain mortality among people who had ADHD-like problems in childhood. Its statistical models highlighted smoking and measures of obesity, with blood pressure also contributing in one model.

That is a useful lead, not a final explanation. The relevant analysis included 8,016 people, only a small subgroup with childhood ADHD-like symptoms, and 15 deaths in that subgroup between ages 44 and 58. Childhood symptoms were identified using historical questionnaires, not current diagnostic assessments. With so few deaths in the subgroup, estimates of underlying pathways are uncertain.

The appropriate conclusion is that smoking, weight-related risk, and blood pressure are plausible targets for prevention, not that this one study has proved what causes ADHD-associated premature deaths.

4. The practical difficulty of maintaining healthcare

Many adults with ADHD describe difficulty organizing appointments, keeping track of prescriptions, following multistep treatment plans, or maintaining routines. Those are executive-function challenges, not a lack of concern for their own health.

Researchers in the 2026 mortality review discuss difficulties engaging with healthcare, as well as education and socioeconomic disadvantage, as plausible contributors to physical-health disparities. These pathways are difficult to separate from the effects of ADHD symptoms, other diagnoses, and healthcare access.

This is also why better outcomes cannot be reduced to medication alone. Accessible primary care, mental health treatment, practical accommodations, and continuity of support may all matter, even where mortality-specific evidence remains incomplete.

The question of why ADHD develops is separate from the question of what predicts long-term health outcomes. For the first, see our examination of ADHD, genetics, and childhood stress.

Can ADHD medication reduce the risk of early death?

ADHD medication use is associated with lower mortality in several observational studies, but researchers have not established that taking medication directly prevents a specific percentage of deaths.

The 2026 meta-analysis reported a pooled hazard ratio of 0.75 when comparing people with ADHD who used medication with people with ADHD who did not. This corresponds to a 25% lower observed mortality hazard in the treated group.

The result came from just three studies. The authors specifically warned about confounding: people who receive treatment can differ from those who do not in ADHD severity, other illnesses, socioeconomic circumstances, access to care, and ability to maintain treatment. These differences can influence mortality independently of medication.

The original researchers explicitly cautioned against interpreting this pooled association as proof of a causal protective effect.

A Swedish study puts the difference into real numbers

One of the most useful studies for understanding the size of the association was a 2024 JAMA study of 148,578 people in Sweden, aged 6 to 64, who had received a new ADHD diagnosis. Researchers compared strategies involving starting ADHD medication within three months of diagnosis with not starting during that interval, then estimated mortality over two years using methods designed to approximate a randomized trial.

The estimated difference in all-cause mortality was 8.9 fewer deaths per 10,000 people over two years, or about 0.089 percentage points. These are adjusted modeled risks, not a simple tally of observed deaths or a guarantee of what would happen if any given person started medication.

Importantly, the difference in unnatural-cause mortality was statistically significant, while the difference in natural-cause mortality was not. That suggests possible benefits may be more apparent for some pathways than others, but it does not prove which deaths medication prevented.

The study cannot answer what happens to life expectancy over an entire lifetime. It followed people for two years after diagnosis and included children, adolescents, and adults with very different underlying risks.

What about accidents, substance use, and suicidal behavior?

A 2025 study in The BMJ using Swedish national records examined outcomes other than death. Starting ADHD medication was associated with lower rates of first recorded suicidal behaviors, substance misuse, and transport accidents over two years. The association with first recorded accidental injuries overall was not statistically significant.

These findings offer possible explanations for a lower risk of some serious outcomes. But a reduction in nonfatal suicidal behavior is not identical to a demonstrated reduction in deaths by suicide, and the observational design still limits causal claims.

The 2024 JAMA and 2025 BMJ papers also used substantially overlapping Swedish registry populations. They provide different analyses of related data, not wholly independent confirmation from separate groups of patients.

Does medication eliminate most of ADHD’s excess mortality risk?

No study discussed here establishes that. A 25% lower mortality hazard among medication users cannot be subtracted directly from the 71% higher mortality hazard associated with ADHD. Those figures come from different comparisons, populations, and research models.

Nor can medication’s association with mortality be converted into “years of life restored” using the UK life-expectancy study. The evidence does not support that calculation.

Medication can be an important part of evidence-based ADHD care. The mortality studies strengthen the case for ensuring people can access appropriate assessment and treatment, but they do not justify either promising a longer life from a prescription or portraying treatment as the only meaningful response.

If ADHD medication may help, why are there cardiovascular concerns?

This apparent contradiction is one of the most important parts of the evidence.

A study published in JAMA Psychiatry in 2024 examined cardiovascular disease in Swedish people with ADHD. Longer cumulative ADHD medication exposure was associated with higher rates of cardiovascular disease diagnoses, particularly hypertension and arterial disease.

For example, compared with nonuse, three to five years of cumulative medication use was associated with an adjusted odds ratio of 1.27 for cardiovascular disease. More than five years was associated with an adjusted odds ratio of 1.23. These results were observational, and an odds ratio for developing a cardiovascular condition is not a mortality risk ratio.

The findings can coexist with studies showing lower overall mortality among medication users. A treatment might plausibly help with some risks while carrying other risks that require monitoring. The available studies do not tell us the exact balance for every medication or every patient.

This is why medication decisions should be individualized. The UK’s NICE ADHD guideline recommends a medical and cardiovascular assessment before prescribing and checks of heart rate and blood pressure before and after dose changes and every six months during treatment. The guideline also recommends periodic review of benefits, adverse effects, and ongoing need.

Anyone concerned about side effects, blood pressure, or whether treatment is appropriate should discuss it with the prescribing clinician rather than starting, stopping, or changing medication based on a population-level mortality headline.

Is the mortality risk the same for every person with ADHD?

No. The available research does not support one uniform risk estimate across children, adolescents, adults, men, women, and people with different health histories.

The 2015 Danish cohort found different relative mortality associations depending on the age at which ADHD was diagnosed and the presence of co-occurring disorders. The 2025 UK life-expectancy study reported different modeled gaps for men and women, but those figures depend on the characteristics of the diagnosed population.

An adult receiving their first diagnosis is not necessarily someone whose ADHD began in adulthood. ADHD is a neurodevelopmental condition whose symptoms begin in childhood, even if recognition and treatment happen much later.

Risk may also vary with co-occurring depression, substance-use problems, cardiovascular health, social circumstances, and access to ongoing care. The 2026 meta-analysis lacked sufficiently consistent data to generate reliable pooled subgroup estimates for these factors.

It is therefore misleading to treat “ADHD” as a single lifespan category. The diagnosis matters, but it is not the only information that matters.

What can people with ADHD actually do about the findings?

The research should not leave readers with a frightening statistic and no useful interpretation. It points toward areas of care that deserve attention, while leaving open whether any particular intervention has been proved to extend lifespan specifically in people with ADHD.

Seek a thorough assessment and a treatment plan that fits the individual. The National Institute of Mental Health describes medication, psychotherapy, behavioral interventions, and practical skills training as established approaches to managing ADHD symptoms and improving functioning. Treatment should reflect age, symptoms, co-occurring conditions, preferences, and adverse effects.

Do not overlook other mental health conditions. Depression, anxiety, substance-use disorders, and suicidal thinking require their own assessment and appropriate care. For children and adolescents, the American Academy of Pediatrics’ ADHD guideline specifically recommends screening for co-occurring emotional, developmental, and physical conditions.

Treat preventive physical healthcare as part of ADHD care. Smoking cessation, blood pressure checks, assessment of weight-related and metabolic risks, and ordinary age-appropriate preventive care matter irrespective of whether ADHD causes or merely accompanies particular health problems. The emerging mortality research gives additional reason not to let these needs fall through the cracks.

Make follow-through easier, rather than relying on memory alone. Appointment reminders, automated prescription refills where available, written treatment plans, help with scheduling, and coordination between mental health and primary care clinicians can reduce practical barriers. These are reasonable supports for executive-function difficulties, although the mortality studies do not measure how many deaths such tools might prevent.

Address concrete safety risks where relevant. People dealing with distraction while driving, substance use, severe sleep problems, or other safety-related difficulties should work with qualified professionals on specific strategies rather than assuming all people with ADHD have the same risks.

Review medications regularly. Benefits, side effects, cardiovascular monitoring, and changing needs should be assessed over time. Neither the mortality data nor cardiovascular studies support a one-size-fits-all decision about medication.

The larger message is about continuity of care and preventable health disparities, not about expecting people with ADHD to compensate for complex challenges through willpower alone.

What do researchers still not know?

Several important questions remain unresolved:

• Causation: How much of the excess mortality is driven directly by ADHD-related traits, and how much by co-occurring health conditions, social factors, or differences in diagnosis and care?
• Long-term treatment effects: Does medication itself reduce deaths over decades, and for whom? Observational results cannot yet provide a definitive answer.
• Individual prognosis: How do risks differ by age, ADHD presentation, sex, physical health, treatment history, and socioeconomic circumstances?
• Prevention: Which combinations of ADHD care, mental health support, injury prevention, and physical healthcare actually narrow the life-expectancy gap?
• Generalizability: How well do findings from particular national registers and diagnosed populations describe people with undiagnosed ADHD or those living in different healthcare systems?

The 2026 review also had major between-study variation and limited ability to explore these questions. That is a reason for more precise research, not a reason to ignore the observed disparity.

Frequently asked questions

Can someone with ADHD live a normal lifespan?

Yes. The studies describe differences in group-level mortality and modeled life expectancy. They do not set an age limit for any person with ADHD. Many people with ADHD live long lives, and the purpose of understanding excess risk is to identify health needs that may be addressed.

Does untreated ADHD shorten life expectancy?

Researchers have documented higher mortality among people with ADHD and lower observed mortality among some medication-treated groups. But there is no reliable universal estimate of years lost specifically because an individual’s ADHD went untreated. Treated and untreated populations can differ in ways that affect mortality apart from medication.

Do ADHD stimulants make people live longer?

That has not been proved. Some studies associate ADHD medication with lower mortality or fewer serious adverse events, while other research identifies cardiovascular risks associated with longer medication exposure. The best treatment choice depends on individual circumstances and clinical monitoring.

Does a child with ADHD face the same early-death risk reported in adults?

Not necessarily. Mortality patterns and baseline risks differ greatly across ages. The 2026 pooled estimate combines diverse populations and cannot predict an individual child’s lifespan. Early assessment, appropriate treatment, safety, and support are more useful responses than applying an adult population estimate to a child.

Is ADHD itself a fatal disease?

No. ADHD is a neurodevelopmental condition, not an illness that inevitably causes death. Research links ADHD to higher rates of several adverse outcomes, some involving co-occurring conditions or potentially modifiable health and social risks. Understanding those pathways is more informative than describing ADHD as inherently fatal.

The bottom line

The evidence that ADHD is associated with premature mortality is serious and should not be dismissed. A 2026 review found higher hazards of death from multiple causes, and earlier UK research estimated a sizable life-expectancy gap among adults who had received an ADHD diagnosis.

But the studies do not show that every person with ADHD will lose seven to nine years of life. Nor do they prove that medication erases most of the excess risk.

What they reveal is a broader, potentially addressable health inequality. Injuries, co-occurring mental health conditions, physical health risks, treatment barriers, and social circumstances all warrant closer attention. Better diagnosis, evidence-based treatment, preventive medicine, and sustained support may help address those problems, even where the precise effects on longevity remain uncertain.

ADHD is associated with higher mortality in population studies. It is not an individual sentence of early death.

References and Further Reading

Systematic Reviews and Life-Expectancy Research

• Corrigan et al. (2026), “Mortality Among People With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis,” JAMA Network Open. The central October 2026 review. Reports pooled hazard ratios for all-cause, suicide, injury, natural-cause, and medication-associated mortality, together with substantial limitations and between-study heterogeneity.
• O’Nions et al. (2025), “Life expectancy and years of life lost for adults with diagnosed ADHD in the UK,” The British Journal of Psychiatry. Original matched-cohort study behind the 6.78- and 8.64-year life-expectancy estimates and their limitations.
• Catalá-López et al. (2022), “Mortality in Persons With Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder,” JAMA Pediatrics. Earlier meta-analysis that provides historical context for what the 2026 evidence synthesis adds.

Mortality Patterns and Possible Mechanisms

• Dalsgaard et al. (2015), “Mortality in children, adolescents, and adults with ADHD,” The Lancet. Danish nationwide study providing observed absolute mortality rates per 10,000 person-years and evidence on injuries and age at diagnosis.
• Sun et al. (2019), “Association of Psychiatric Comorbidity With the Risk of Premature Death Among Children and Adults With ADHD,” JAMA Psychiatry. Swedish cohort analysis examining how co-occurring psychiatric conditions relate to mortality disparities.
• Thapar et al. (2026), “Association between childhood ADHD problems and premature mortality,” Frontiers in Psychiatry. Exploratory UK birth-cohort analysis of smoking and cardiovascular risk pathways. Its small ADHD-subgroup death count limits causal conclusions.

ADHD Medication, Mortality, and Cardiovascular Risk

• Li et al. (2024), “ADHD Pharmacotherapy and Mortality in Individuals With ADHD,” JAMA. Swedish target-trial emulation providing adjusted two-year mortality estimates for medication initiation versus noninitiation, including absolute risk differences.
• Zhang et al. (2025), “ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality,” The BMJ. Related Swedish registry analysis of nonfatal outcomes; its study population substantially overlaps with the earlier mortality analysis.
• Zhang et al. (2024), “ADHD Medications and Long-Term Risk of Cardiovascular Diseases,” JAMA Psychiatry. Observational study reporting associations between longer medication exposure and cardiovascular diagnoses, particularly hypertension.

Clinical Guidance and Support

• National Institute of Mental Health, “Attention-Deficit/Hyperactivity Disorder: What You Need to Know”. Evidence-based overview of ADHD, assessment, treatment, and practical support.
• National Institute for Health and Care Excellence, ADHD Diagnosis and Management Guideline NG87. UK clinical recommendations on evaluation, medications, cardiovascular monitoring, and follow-up.
• American Academy of Pediatrics, Clinical Practice Guideline for ADHD in Children and Adolescents. Pediatric guidance, including screening for co-occurring mental, developmental, and physical health conditions.
• 988 Suicide & Crisis Lifeline, Get Help. Official US crisis-support resource for readers who need immediate assistance.

Editorial currency note: Research reviewed through October 26, 2026. Mortality estimates are population-level associations and may change as new studies are published. Clinical treatment and monitoring recommendations should be checked against current local guidance. This article is for informational purposes and is not a substitute for individualized medical advice.